Health Executive Insights
Jamie Stanistreet
Retired Managing Director Medtronic Australia and New Zealand
talks Medical Technology in Australia and the Asia-Pacific
▶︎ Career turning points
▶︎ Current industry roles
▶︎ Innovation hurdles
▶︎ Asia-Pacific health market
▶︎ Trends in patient centricity
▶︎ Opportunity for MedTech
▶︎ Showing value of new technology
▶︎ Timely access to treatment
-
Value-Based Health Care : Dental Health Services Victoria Case Study
Dental Health Services Victoria has implemented a value based health model for oral health, around the patient and the clinician that included both during co-design. This has been possible with a single oral health data system for the state of Victoria and staff keeping in mind the value and outcomes that patients seek.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
